New York, USA - November 29, 2023 - While the severity of the COVID-19 pandemic has somewhat diminished since its early months in 2020, this decline is not indicative of a reduction in infections but rather a result of the virus's widespread prevalence, leading to repeated infections in individuals. With its substantial background in tackling SARS-CoV-2, Creative Biolabs provides researchers around the world with all-encompassing services for the development of vaccines and drugs.
Within the domain of SARS-CoV-2 vaccine development, Creative Biolabs facilitates the exploration and advancement of diverse types of vaccines. These include pre-development computer-simulated vaccine design, an optimized platform for vaccine formulation during development, and post-development vaccine analysis and identification.
Offering a one-stop solution for vaccine development, these services accelerate research from identifying potential targets to analyzing immune responses and evaluating challenging infection models.
Expanding its scope beyond vaccine development, Creative Biolabs plays a proactive role in the exploration and advancement of drugs targeting SARS-CoV-2. An advanced SARS-CoV-2 cytopathic effect assay service offers researchers a dependable tool to evaluate the efficacy of candidate vaccines or drugs in simulated infection environments.
Explaining the significance of their services, a virus expert from Creative Biolabs stated, "CPE testing simulates virus infection in an in vitro culture system, evaluating the inhibitory effect of candidate vaccines on virus replication. Creative Biolabs' professional team provides clients with efficient and precise data, offering robust support for vaccine development."
Furthermore, Creative Biolabs places a specific focus on the virus's surface protein, particularly the receptor-binding domain (RBD), a crucial step in the virus's entry into host cells. Creative Biolabs has successfully developed a range of exceptionally potent monoclonal antibodies exhibiting outstanding activity.
"To enhance the feasibility of monoclonal antibodies from the SARS-CoV-2 surface proteins, Creative Biolabs' humanized antibody mouse models, simulating the response of the human immune system, generate antibodies more akin to those in the human body," emphasized the innovativeness of this model system.
Creative Biolabs also provides other advanced technologies and platforms for combating SARS-CoV-2. These include in-house-developed cell lines for COVID-19 research, such as ACE2-enhanced or knockout (KO) cell lines, neutralization assays, reverse genetic systems for target screening and drug discovery, and a high-quality animal model development platform.
For more detailed information on the SARS-CoV-2-related services offered by Creative Biolabs, please visit https://sars-cov-2.creative-biolabs.com.
About
Creative Biolabs has a highly comprehensive platform dedicated to advancing the forefront of vaccine and drug development. Creative Biolabs not only provides robust technical support and solutions for current pandemic responses but also prepares for future viral threats.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://sars-cov-2.creative-biolabs.com
